Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CTLA-4 monoclonal antibody XTX101

A fully humanized, Fc-engineered monoclonal antibody with masked antigen-binding regions directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration and the activation of the antigen-binding regions via cleavage by proteases that are upregulated in the tumor microenvironment (TME), anti-CTLA-4 monoclonal antibody XTX101 targets and binds to CTLA-4 expressed on T cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:XTX 101
XTX-101
XTX101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search